Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease

Molecular Psychiatry

Volumn 19, Issue 3, 2014, Pages 358-367

  Drui, G ^a,b   Carnicella, S ^a,b   Carcenac, C ^a,b   Favier, M ^a,b   Bertrand, A ^a,b   Boulet, S ^a,b   Savasta, M ^a,b,c  

^a GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^b UNIV GRENOBLE ALPES   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Apathy; Dopamine; Mesocorticolimbic; Motivation; Nigrostriatal; Parkinson's disease

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMAN; MALE; MOTIVATION; MOTOR DYSFUNCTION; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

AFFECT; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; MALE; MICROINJECTIONS; MOTIVATION; NEURAL PATHWAYS; OXIDOPAMINE; PARKINSON DISEASE; RATS; SUBSTANTIA NIGRA; VENTRAL TEGMENTAL AREA;

EID: 84894544413     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.3     Document Type: Article

References (49)

1. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999; 122(Pt 8): 1437-1448
2. Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: An update. Trends Neurosci 2007; 30: 194-202
3. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-474
4. Krack P, Hariz MI, Baunez C, Guridi J, Obeso JA. Deep brain stimulation: From neurology to psychiatry? Trends Neurosci 2010; 33: 474-484
5. Thobois S, Ardouin C, Lhommée E, Klinger H, Lagrange C, Xie J et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: Predictors and underlying mesolimbic denervation. Brain 2010; 133: 1111-1127
6. Le Moal M, Simon H. Mesocorticolimbic dopaminergic network: Functional and regulatory roles. Physiol Rev 1991; 71: 155-234
7. Nieoullon A, Coquerel A. Dopamine: A key regulator to adapt action, emotion, motivation and cognition. Curr Opin Neurol 2003; 16(Suppl 2): S3-S9
8. Koob GF, Simon H, Herman JP, Le Moal M. Neuroleptic-like disruption of the conditioned avoidance response requires destruction of both the mesolimbic and nigrostriatal dopamine systems. Brain Res 1984; 303: 319-329
9. Lindgren HS, Dunnett SB. Cognitive dysfunction and depression in Parkinson's disease: What can be learned from rodent models? Eur J Neurosci 2012; 35: 1894-1907
10. Schwarting RK, Huston JP. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 1996; 49: 215-266
11. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Elesvier Academic Press: San Diego, 1998
12. Boulet S, Lacombe E, Carcenac C, Feuerstein C, Sgambato-Faure V, Poupard A et al. Subthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulata. J Neurosci 2006; 26: 10768-10776
13. Voorn P, Vanderschuren LJ, Groenewegen HJ, Robbins TW, Pennartz CM. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci 2004; 27: 468-474
14. Dentresangle C, Le Cavorsin M, Savasta M, Leviel V. Increased extracellular DA and normal evoked DA release in the rat striatum after a partial lesion of the substantia nigra. Brain Res 2001; 893: 178-185
15. Olsson M, Nikkhah G, Bentlage C, Bjorklund A. Forelimb akinesia in the rat Parkinson model: Differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995; 15: 3863-3875
16. Takaki E, Fujimoto M, Sugahara K, Nakahari T, Yonemura S, Tanaka Y et al. Maintenance of olfactory neurogenesis requires HSF1, a major heat shock transcription factor in mice. J Biol Chem 2006; 281: 4931-4937
17. Lelan F, Boyer C, Thinard R, Rémy S, Usal C, Tesson L et al. Effects of human alpha-synuclein A53T-A30P mutations on svz and local olfactory bulb cell proliferation in a transgenic rat model of Parkinson disease. Parkinsons Dis 2011; 2011: 987084
18. Pecina S, Cagniard B, Berridge KC, Aldridge JW, Zhuang X. Hyperdopaminergic mutant mice have higher 'wanting' but not 'liking' for sweet rewards. J Neurosci 2003; 23: 9395-9402
19. Baunez C, Dias C, Cador M, Amalric M. The subthalamic nucleus exerts opposite control on cocaine and 'natural' rewards. Nat Neurosci 2005; 8: 484-489
20. Carnicella S, Kharazia V, Jeanblanc J, Janak PH, Ron D. GDNF is a fast-Acting potent inhibitor of alcohol consumption and relapse. Proc Natl Acad Sci USA 2008; 105: 8114-8119
21. Richardson NR, Roberts DC. Progressive ratio schedules in drug self-Administration studies in rats: A method to evaluate reinforcing efficacy. J Neurosci Methods 1996; 66: 1-11
22. Belin D, Berson N, Balado E, Piazza PV, Deroche-Gamonet V. High-novelty-preference rats are predisposed to compulsive cocaine self-Administration. Neuropsychopharmacology 2011; 36: 569-579
23. File SE, Hyde Jr. Can social interaction be used to measure anxiety? Br J Pharmacol 1978; 62: 19-24
24. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988; 318: 876-880
25. Kirik D, Rosenblad C, Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998; 152: 259-277
26. Marin RS. Apathy: A neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991; 3: 243-254
27. Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortexbasal ganglia circuits. Cereb Cortex 2006; 16: 916-928
28. Schmidt L, d'Arc BF, Lafargue G, Galanaud D, Czernecki V, Grabli D et al. Disconnecting force from money: Effects of basal ganglia damage on incentive motivation. Brain 2008; 131: 1303-1310
29. Czernecki V, Schüpbach M, Yaici S, Lévy R, Bardinet E, Yelnik J et al. Apathy following subthalamic stimulation in Parkinson disease: A dopamine responsive symptom. Mov Disord 2008; 23: 964-969
30. Ettenberg A. Opponent process properties of self-Administered cocaine. Neurosci Biobehav Rev 2004; 27: 721-728
31. Hodos W. Progressive ratio as a measure of reward strength. Science 1961; 134: 943-944
32. Deroche-Gamonet V, Piat F, Le Moal M, Piazza PV. Influence of cue-conditioning on acquisition, maintenance and relapse of cocaine intravenous self-Administration. Eur J Neurosci 2002; 15: 1363-1370
33. Olds J. Drives and Reinforcements: Behavioral Studies of Hypothalamic Functions. (Raven Press: New York, 1977).
34. Palmiter RD. Dopamine signaling in the dorsal striatum is essential for motivated behaviors: Lessons from dopamine-deficient mice. Ann NY Acad Sci 2008; 1129: 35-46
35. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008; 156: 830-840
36. Brown CA, Campbell MC, Karimi M, Tabbal SD, Loftin SK, Tian LL et al. Dopamine pathway loss in nucleus accumbens and ventral tegmental area predicts apathetic behavior in MPTP-lesioned monkeys. Exp Neurol 2012; 236: 190-197
37. Belin D, Jonkman S, Dickinson A, Robbins TW, Everitt BJ. Parallel and interactive learning processes within the basal ganglia: Relevance for the understanding of addiction. Behav Brain Res 2009; 199: 89-102
38. Bromberg-Martin ES, Matsumoto M, Hikosaka O. Dopamine in motivational control: Rewarding, aversive, and alerting. Neuron 2010; 68: 815-834
39. Ikemoto S. Dopamine reward circuitry: Two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev 2007; 56: 27-78
40. Wise RA. Roles for nigrostriatal - not just mesocorticolimbic - dopamine in reward and addiction. Trends Neurosci 2009; 32: 517-524
41. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci 2006; 7: 464-476
42. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E et al. The dopamine D3 receptor: A therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006; 5: 25-43
43. Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease - epidemiology, mechanisms and management. Nat Rev Neurol 2011; 8: 35-47
44. Barone P. Treatment of depressive symptoms in Parkinson's disease. Eur J Neurol 2011; 18(Suppl 1): 11-15
45. Barnhart WJ, Makela EH, Latocha MJ. SSRI-induced apathy syndrome: A clinical review. J Psychiatr Pract 2004; 10: 196-199
46. Adell A, Artigas F. The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci Biobehav Rev 2004; 28: 415-431
47. Barone P. Neurotransmission in Parkinson's disease: Beyond dopamine. Eur J Neurol 2010; 17: 364-376
48. Navailles S, Benazzouz A, Bioulac B, Gross C, De Deurwaerdere P. High-frequency stimulation of the subthalamic nucleus and L-3,4- dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J Neurosci 2010; 30: 2356-2364
49. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Elesvier Academic Press: San Diego, 2005.